Loading...
Loading...
Alexion Pharmaceuticals, Inc.
ALXN today announced that researchers
have presented data from a single-arm, open-label, investigator-initiated
Phase 2 study of eculizumab (Soliris^®) as an investigational therapy in 14
patients with severe, relapsing neuromyelitis optica (NMO), a
life-threatening, ultra-rare neurological disorder. The study met its primary
efficacy endpoint with high degrees of clinical and statistical significance.
Clinically and statistically significant improvements were also observed in
key secondary endpoints. Data were presented today at a Scientific Symposium
Oral Session at the American Neurological Association annual meeting in
Boston, Mass.^1
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in